secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001140361-24-014613
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Therapeutics prices $75M public offering of 16.7M shares at $4.50 per share
--------------------------------------------------------------------------------

- Offering of 16,666,667 shares at $4.50 per share; gross proceeds ~$75M, net ~$69.8M.
- Underwriters granted 30-day option to purchase up to 2,500,000 additional shares.
- Proceeds to advance Anaphylm (epinephrine) sublingual film and Libervant (diazepam) buccal film.
- Closing expected on or about March 22, 2024; Leerink Partners and Piper Sandler lead.
- Company expects net proceeds plus existing cash to fund operations through December 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000114036124014613/0001140361-24-014613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000114036124014613/ny20024600x3_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-014613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer